Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5517 |
Name | stomach carcinoma |
Definition | A stomach cancer that is located_in the stomach. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer stomach cancer stomach carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR2 act mut | S-49076 | stomach carcinoma | sensitive | detail... |
CDKN2A R80* | Palbociclib | stomach carcinoma | sensitive | detail... |
FGFR2 amp | PRN1371 | stomach carcinoma | sensitive | detail... |
FGFR2 amp | RO4987655 | stomach carcinoma | no benefit | detail... |
FGFR2 amp | RO5126766 | stomach carcinoma | no benefit | detail... |
FGFR2 amp | Zoligratinib | stomach carcinoma | sensitive | detail... |
BRAF mutant | KO-947 | stomach carcinoma | predicted - sensitive | detail... |
NRAS mutant | KO-947 | stomach carcinoma | predicted - sensitive | detail... |
FGFR2 amp | CPL304110 | stomach carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT01183559 | Phase I | Carboplatin + Fluorouracil + Paclitaxel + Vandetanib | A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery | Completed | USA | 0 |
NCT02065765 | Phase II | Ramucirumab | International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer | No longer available | NLD | GRC | DEU | AUT | 1 |
NCT02274012 | Phase II | Afatinib + Paclitaxel | Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer | Withdrawn | 0 | |
NCT02344810 | Phase Ib/II | AMG 337 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | Withdrawn | USA | 0 |
NCT02488759 | Phase Ib/II | Nivolumab | A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) | Completed | USA | NLD | GBR | FRA | ESP | DEU | BEL | 4 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02773524 | Phase III | Regorafenib | A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEII) | Unknown status | USA | NZL | CAN | AUS | 3 |
NCT02830594 | Phase II | Pembrolizumab | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | Completed | USA | 0 |
NCT02892123 | Phase I | Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | Active, not recruiting | USA | CAN | 1 |
NCT03008278 | Phase Ib/II | Olaparib + Ramucirumab | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03288350 | Phase II | Cisplatin + Docetaxel + Fluorouracil Avelumab | mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) | Unknown status | CAN | 0 |
NCT03474640 | Phase I | Toripalimab-tpzi | Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | Unknown status | USA | 0 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT04047862 | Phase I | BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | Completed | USA | NZL | AUS | 3 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | AUS | 0 |
NCT04254107 | Phase I | SGN-TGT Pembrolizumab + SGN-TGT | A Safety Study of SGN-TGT in Patients With Advanced Cancer | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Terminated | USA | POL | NOR | ITA | ISR | HUN | FRA | ESP | DEU | CAN | 4 |
NCT04594811 | Phase II | Nivolumab Nivolumab + NT-I7 | NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma | Terminated | USA | POL | 0 |
NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT04752215 | Phase I | BI 765049 + Ezabenlimab BI 765049 | A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | Active, not recruiting | USA | CAN | 0 |
NCT04879368 | Phase III | Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan | RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) | Active, not recruiting | USA | ITA | ESP | DEU | AUT | AUS | 3 |
NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Active, not recruiting | USA | GBR | 0 |
NCT05143970 | Phase I | IPH5301 IPH5301 + Paclitaxel + Trastuzumab | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) | Recruiting | FRA | 0 |
NCT05163041 | Phase Ib/II | BT7480 BT7480 + Nivolumab | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Recruiting | USA | GBR | 0 |
NCT05548634 | Phase I | TAVO412 | A Study of TAVO412 in Patients With Cancer (TAVO412) | Active, not recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Recruiting | USA | 0 |
NCT06131840 | Phase I | SGN-CEACAM5C | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Recruiting | USA | SWE | NLD | GBR | ESP | CAN | 0 |